Co-Diagnostics, Inc. to Host Booth at Medlab Africa in Cape Town on Oct 22-24, 2024
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced its participation in Africa Health/Medlab Africa in Cape Town, South Africa from October 22-24, 2024. The conference is described as the largest gathering of healthcare companies in the sub-Saharan region. Co-Dx views this trade show as an opportunity to gain insight into markets expected to play a significant role in the company's future.
The company highlighted the importance of the African market, citing a WHO report estimating 2.5 million tuberculosis cases in the African Region in 2021. Co-Dx is developing several infectious disease tests, including one for TB, on its upcoming Co-Dx™ PCR at-home and point-of-care platform. The company also mentioned its Logix Smart® Mpox (2-Gene) RUO test, which is expected to retain full reactivity against known mpox strains.
Interested parties can visit Co-Dx at Booth H1/B1 during the conference.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) ha annunciato la sua partecipazione all'Africa Health/Medlab Africa che si terrà a Cape Town, Sudafrica, dal 22 al 24 ottobre 2024. La conferenza è descritta come il più grande raduno di aziende sanitarie nella regione sub-sahariana. Co-Dx considera questa fiera come un'opportunità per ottenere informazioni sui mercati che si prevede giocheranno un ruolo significativo nel futuro dell'azienda.
L'azienda ha evidenziato l'importanza del mercato africano, citando un rapporto dell'OMS che stima 2,5 milioni di casi di tubercolosi nella regione africana nel 2021. Co-Dx sta sviluppando diversi test per malattie infettive, incluso uno per la tubercolosi, sulla sua prossima piattaforma Co-Dx™ PCR per uso domestico e per assistenza sanitaria. L'azienda ha inoltre menzionato il suo test Logix Smart® Mpox (2-Gene) RUO, che si prevede mantenga piena reattività contro ceppi noti di mpox.
Le parti interessate possono visitare Co-Dx allo Stand H1/B1 durante la conferenza.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) anunció su participación en Africa Health/Medlab Africa en Ciudad del Cabo, Sudáfrica, del 22 al 24 de octubre de 2024. La conferencia se describe como el mayor encuentro de empresas de salud en la región subsahariana. Co-Dx ve esta feria como una oportunidad para obtener información sobre los mercados que se espera desempeñen un papel significativo en el futuro de la empresa.
La compañía resaltó la importancia del mercado africano, citando un informe de la OMS que estima 2.5 millones de casos de tuberculosis en la Región Africana en 2021. Co-Dx está desarrollando varias pruebas para enfermedades infecciosas, incluida una para la tuberculosis, en su próxima plataforma Co-Dx™ PCR para uso en el hogar y en el punto de atención. La empresa también mencionó su prueba Logix Smart® Mpox (2-Gene) RUO, que se espera mantenga plena reactividad contra cepas conocidas de mpox.
Las partes interesadas pueden visitar a Co-Dx en el Stand H1/B1 durante la conferencia.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX)는 2024년 10월 22일부터 24일까지 남아프리카 케이프타운에서 열리는 Africa Health/Medlab Africa에 참여한다고 발표했습니다. 이 회의는 사하라 이남 지역의 의료 회사들이 모이는 최대 행사로 설명됩니다. Co-Dx는 이 무역 전시회를 회사의 미래에서 중요한 역할을 할 것으로 예상되는 시장에 대한 통찰력을 얻을 기회로 보고 있습니다.
회사는 2021년 아프리카 지역에서 250만 건의 결핵 사례를 추정한 WHO 보고서를 인용하며 아프리카 시장의 중요성을 강조했습니다. Co-Dx는 다가오는 Co-Dx™ PCR 가정용 및 현장 사용 플랫폼에서 결핵을 포함한 여러 전염병 테스트를 개발하고 있습니다. 또한, 회사는 알려진 mpox 균주에 대한 완전한 반응성을 유지할 것으로 예상되는 Logix Smart® Mpox (2-Gene) RUO 테스트도 언급했습니다.
관심 있는 분들은 회의 기간 동안 Co-Dx의 부스 H1/B1을 방문할 수 있습니다.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) a annoncé sa participation à Africa Health/Medlab Africa à Cape Town, Afrique du Sud, du 22 au 24 octobre 2024. La conférence est décrite comme le plus grand rassemblement d'entreprises de santé dans la région subsaharienne. Co-Dx considère cette foire comme une opportunité d'obtenir des informations sur des marchés qui devraient jouer un rôle significatif dans l'avenir de l'entreprise.
L'entreprise a souligné l'importance du marché africain, citant un rapport de l'OMS estimant 2,5 millions de cas de tuberculose dans la région africaine en 2021. Co-Dx développe plusieurs tests pour des maladies infectieuses, y compris un pour la tuberculose, sur sa prochaine plateforme Co-Dx™ PCR à domicile et point de soin. L'entreprise a également mentionné son test Logix Smart® Mpox (2-Gene) RUO, qui devrait maintenir une réactivité complète contre des souches connues de mpox.
Les parties intéressées peuvent visiter Co-Dx au Stand H1/B1 pendant la conférence.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) gab seine Teilnahme an der Africa Health/Medlab Africa in Kapstadt, Südafrika, vom 22. bis 24. Oktober 2024 bekannt. Die Konferenz wird als das größte Treffen von Gesundheitsunternehmen in der Subsahara-Region beschrieben. Co-Dx betrachtet diese Messe als eine Gelegenheit, Einblicke in Märkte zu gewinnen, die eine bedeutende Rolle in der Zukunft des Unternehmens spielen werden.
Das Unternehmen hob die Bedeutung des afrikanischen Marktes hervor und verwies auf einen WHO-Bericht, der für das Jahr 2021 schätzte, dass es 2,5 Millionen Tuberkulosefälle in der afrikanischen Region gibt. Co-Dx entwickelt mehrere Tests für Infektionskrankheiten, darunter einen für TB, auf seiner bevorstehenden Co-Dx™ PCR-Plattform für zu Hause und in der klinischen Anwendung. Das Unternehmen erwähnte auch seinen Logix Smart® Mpox (2-Gene) RUO-Test, der voraussichtlich eine vollständige Reaktivität gegen bekannte mpox-Stämme aufrechterhalten wird.
Interessierte Parteien können Co-Dx am Stand H1/B1 während der Konferenz besuchen.
- None.
- None.
The conference website describes it as the largest gathering of healthcare companies, technology, products and services in the sub-Saharan region, catering to an audience of distributors, government representatives, laboratory executives, and purchasing/procurement managers from the South African Development Community region and around the world, who attend to meet with world-class suppliers and manufacturers.
Co-Dx believes that the trade show will contribute valuable insight into markets that are anticipated to play an important role in the Company's future. In a report issued in September 2023, the WHO estimated that 2.5 million people contracted tuberculosis (TB) in the African Region in 2021, while noting that a large gap also remains between estimated TB cases and those identified. Co-Dx has several infectious disease tests in varying stages of development on the Company's upcoming Co-Dx™ PCR at-home and point-of-care platform*, including a test for TB.
Additionally, in an update on its Logix Smart® Mpox (2-Gene) RUO test last month, the Company reported that an in silico analysis shows that the test should retain full reactivity against known mpox strains. This followed the respective declarations in August by the Africa CDC and WHO of mpox (formerly monkeypox) as a public health emergency of continental security (PHECS) and a public health emergency of international concern (PHEIC).
More information about the conference can be found here. Parties interested in learning more about the Company's diagnostic products are invited to visit Booth H1/B1.
*The Co-Dx PCR platform (including the Co-Dx PCR Home™, Co-Dx PCR Pro™, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale. The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding our preparation for introducing a new PCR diagnostic platform designed for at-home and point-of-care use and that African markets may play an important role in the Company's future. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 14, 2024, and in our other filings with the SEC. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-host-booth-at-medlab-africa-in-cape-town-on-oct-22-24-2024-302281585.html
SOURCE Co-Diagnostics
FAQ
When and where is Co-Diagnostics (CODX) hosting a booth at Medlab Africa?
What infectious disease tests is Co-Diagnostics (CODX) developing for its PCR platform?
How many tuberculosis cases were estimated in the African Region in 2021 according to the WHO report mentioned by Co-Diagnostics (CODX)?
What recent update did Co-Diagnostics (CODX) provide about its Logix Smart® Mpox test?
Where can interested parties find Co-Diagnostics (CODX) at the Medlab Africa conference?
